
Jing Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4980135/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
2	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
3	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
4	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 2017, 170, 1120-1133.e17.	28.9	960
5	An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies AxI as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	7.0	848
6	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	12.8	780
7	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
8	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
9	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
10	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	9.4	555
11	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	9.4	432
12	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	16.8	422
13	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	7.0	388
14	Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	7.0	353
15	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discovery, 2018, 8, 1156-1175.	9.4	323
16	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
17	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
18	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nature Communications, 2020, 11, 4520.	12.8	218

JING WANG

#	Article	IF	CITATIONS
19	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
20	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	27.8	185
21	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	1.8	157
22	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	16.8	145
23	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	1.6	140
24	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
25	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 6852-6861.	7.0	105
26	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	12.4	101
27	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with \hat{I}^2 -blockers. Science Translational Medicine, 2017, 9, .	12.4	96
28	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	1.1	94
29	Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722.	7.0	91
30	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget, 2017, 8, 73419-73432.	1.8	74
31	The deubiquitinase Otub1 controls the activation of CD8+ T cells and NK cells by regulating IL-15-mediated priming. Nature Immunology, 2019, 20, 879-889.	14.5	68
32	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clinical Cancer Research, 2016, 22, 4643-4650.	7.0	64
33	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
34	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	5.0	58
35	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	1.1	57
36	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	5.5	56

Jing Wang

#	Article	IF	CITATIONS
37	NF-lºB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nature Immunology, 2021, 22, 193-204.	14.5	52
38	Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 2017, 8, 86369-86383.	1.8	50
39	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	7.0	48
40	The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. Journal of Clinical Investigation, 2018, 128, 1267-1282.	8.2	48
41	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition. BMC Genomics, 2014, 15, 1079.	2.8	45
42	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	12.4	42
43	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications, 2021, 12, 2606.	12.8	41
44	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	8.8	36
45	PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology, 2019, 157, 163-178.	1.3	34
46	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
47	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	30.7	26
48	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARI ² . Nature Communications, 2022, 13, 2665.	12.8	25
49	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
50	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncolmmunology, 2016, 5, e1234570.	4.6	23
51	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
52	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with <i>T790M</i> mutations. Oncotarget, 2016, 7, 47998-48010.	1.8	21
53	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism, 2021, 9, 33.	5.0	20
54	The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nature Communications, 2021, 12, 6354.	12.8	20

JING WANG

#	Article	IF	CITATIONS
55	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature Communications, 2021, 12, 6340.	12.8	17
56	SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 4095-4105.	2.8	17
57	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Research, 2021, 81, 1398-1412.	0.9	16
58	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research, 2019, 25, 346-357.	7.0	14
59	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. British Journal of Cancer, 2022, 127, 569-576.	6.4	8
60	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
61	Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis. Frontiers in Cell and Developmental Biology, 2022, 10	3.7	6